Cargando…
COVID-19-mediated patient delay caused increased total ischaemic time in ST-segment elevation myocardial infarction
BACKGROUND: The current study aimed to evaluate changes in treatment delay and outcome for ST-segment elevation myocardial infarction (STEMI) in the Netherlands during the first coronavirus disease 2019 (COVID-19) outbreak, thereby comparing regions with a high and low COVID-19 hospitalisation rate....
Autores principales: | Sturkenboom, H. N., van Hattem, V. A. E., Nieuwland, W., Paris, F. M. A., Magro, M., Anthonio, R. L., Algin, A., Lipsic, E., Bruwiere, E., Van den Branden, B. J. L., Polad, J., Tonino, P., Tio, R. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bohn Stafleu van Loghum
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8767528/ https://www.ncbi.nlm.nih.gov/pubmed/35044627 http://dx.doi.org/10.1007/s12471-021-01653-9 |
Ejemplares similares
-
Effect of metformin on outcome in patients undergoing primary percutaneous coronary intervention for st-segment elevation myocardial infarction
por: Posma, RA, et al.
Publicado: (2015) -
Ischaemic electrocardiogram patterns and its association with survival in out-of-hospital cardiac arrest patients without ST-segment elevation myocardial infarction: a COACT trials’ post-hoc subgroup analysis
por: Spoormans, Eva M, et al.
Publicado: (2022) -
Association between public media and trends in new acute coronary syndrome presentations during the first COVID‑19 wave in the Netherlands
por: Derks, L., et al.
Publicado: (2021) -
Prehospital risk assessment in patients suspected of non-ST-segment elevation acute coronary syndrome: a systematic review and meta-analysis
por: Demandt, Jesse P A, et al.
Publicado: (2022) -
Ischaemic cardiovascular risk and prescription of non-steroidal anti-inflammatory drugs for musculoskeletal complaints
por: Koffeman, Aafke R, et al.
Publicado: (2014)